

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2004-08-12** | Period of Report: **2004-08-12**
SEC Accession No. **0001019687-04-001749**

([HTML Version](#) on [secdatabase.com](#))

FILER

LIFEPPOINT INC

CIK: **910523** | IRS No.: **330539168** | State of Incorporation: **DE** | Fiscal Year End: **0331**
Type: **8-K** | Act: **34** | File No.: **001-12362** | Film No.: **04970836**
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address
1205 S. DUPONT ST.
ONTARIO A6 91761

Business Address
1205 S. DUPONT ST.
ONTARIO A6 91761
9094183052

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 12, 2004

LIFEPOINT, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

#33-0539168

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification Number)

1205 S. Dupont Street, Ontario, California

91761

(Address of Principal Executive Offices)

(Zip Code)

(909) 418-3000

Registrant's Telephone Number, Including Area Code

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(c) EXHIBITS

99.1 Copy of Press Release furnished by LifePoint, Inc. (the "Company") dated August 12, 2004, relating to the Company's results for the first quarter ended June 30, 2004, referred to in Item 12 below.

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On August 12, 2004, the Company announced via press release its results for the first quarter ended June 30, 2004. A copy of the Company's press release is attached hereto as Exhibit 99.1. This Form 8-K and the attached exhibit are provided under Item 12 of Form 8-K and are furnished to, but not filed with, the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned therein to be duly authorized.

LIFEPOINT, INC.
(Registrant)

Date: August 12, 2004

By /s/ Craig S. Montesanti

Craig S. Montesanti
Chief Accounting Officer

EXHIBIT 99.1

[LIFEPOINT LOGO]

FOR IMMEDIATE RELEASE

LIFEPOINT, INC. RELEASES FINANCIAL RESULTS FOR THE FIRST
QUARTER ENDED JUNE 30, 2004

ONTARIO, CALIFORNIA - August 12, 2004- LifePoint, Inc. (AMEX: LFP), a leader in non-invasive drug diagnostic technologies and solutions, today announced financial results for the first quarter ended June 30, 2004. Net loss for the first quarter ended June 30, 2004 was \$2.2 million, or \$0.04 per share, compared to a net loss of \$2.0 million, or \$0.05 per share, for the first quarter ended June 30, 2003. Net loss applicable to common stockholders for the first quarter ended June 30, 2004 was \$2.3 million, or \$0.04 per share, compared to a net loss applicable to common stockholders of \$2.4 million, or \$0.06 per share for the first quarter ended June 30, 2003.

"We are pleased to report continued improvement in our balance sheet, as well as progress in our marketing and sales efforts," stated Linda H. Masterson, President and CEO of LifePoint. "The international law enforcement market remains a primary focus for LifePoint. Indeed, we are participating in five significant international studies with another nine scheduled to begin in the next few months and each study represents a substantial business opportunity for LifePoint. Domestically, we have refined our domestic sales focus in a targeted campaign to leverage a very strong endorsement from a well-respected mentor drug court. We have reduced our debt from \$7.8 million in June 2003 down to \$2.1 million, and concurrently, we have improved our cash position from \$67,000 in June 2003 to over \$1.5 million at the end of June 2004, with an additional \$1.44 million added due to early Series D warrant exercises during the first few weeks of July 2004. LifePoint continues to build momentum financially as we position ourselves to capitalize on the significant market opportunities."

LifePoint will host a conference call today at 4:30 PM EDT, (1:30 PM PDT) to discuss the financial results for the first quarter ended June 30, 2004 and to update participants on LifePoint, Inc. To participate, please dial 1-800-299-7635 (DOMESTIC) AND 1-617-786-2901 (INTERNATIONAL) or listen via web cast at www.LifePointInc.com .

--- MORE---

LifePoint, Inc.
Statements of Operations
(Unaudited)

Three Months Ended

	June 30,	
	2004	2003
	-----	-----
	(in millions)	
Net revenues	\$ 0.0	\$ 0.0
COSTS AND EXPENSES:		
Cost of sales	0.8	-
Selling, general and administrative expense	0.8	1.0
Research and development	0.6	0.7
	-----	-----
Total costs and expenses	2.2	1.7
	-----	-----
Loss from operations	(2.2)	(1.7)
Other income (expense) net	-	(0.3)
	-----	-----
Net loss	(2.2)	(2.0)
Less accrued preferred dividend expense	(0.1)	(0.4)
	-----	-----
Loss applicable to common stockholders	\$ (2.3)	\$ (2.4)
Weighted average common shares outstanding	60.6	37.2
Net loss per common share	\$ (0.04)	\$ (0.06)

LifePoint, Inc.
Balance Sheets

	(Unaudited)	(Audited)
	June 30,	March 31,
	2004	2004
	-----	-----
	(in millions)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 1.5	\$ 3.7
Accounts receivable, net	0.1	0.1
Inventories	2.5	2.3
Prepaid expenses and other current assets	0.2	0.2
	-----	-----
Total current assets	4.3	6.3
Property and equipment	4.8	4.8
Less: accumulated depreciation	(3.1)	(2.9)
	-----	-----
Net property and equipment	1.7	1.9
Patents and other intangible assets	0.6	0.6
	-----	-----
Total assets	\$ 6.6	\$ 8.8
	=====	=====

--- MORE---

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued expenses	\$ 1.8	\$ 2.0
Notes payable	0.2	0.1
Notes payable - bank	0.1	0.2
Capital lease, short-term	-	-
	-----	-----
Total current liabilities	2.1	2.3
Long-term debt	-	0.2
	-----	-----
Total liabilities	2.1	2.5
Stockholders' equity:		
Common stock	0.1	0.1
Additional paid-in capital	79.5	78.2
Dividends payable in common stock	0.5	1.3
Accumulated deficit	(75.6)	(73.3)
	-----	-----
Total stockholders' equity	4.5	6.3
Total liabilities and stockholders' equity	\$ 6.6	\$ 8.8

ABOUT LIFEPOINT, INC

LifePoint, Inc., a leader in non-invasive drug diagnostic technologies and solutions, has developed, manufactures and markets the IMPACT TEST SYSTEM - a rapid diagnostic testing, screening and drug monitoring device for use in the workplace, ambulances, pharmacies, law enforcement and home healthcare markets. LifePoint's patented and proprietary technologies for the use of saliva as a non-invasive, blood-comparable test specimen, used in conjunction with the flow immunosensor technology licensed from the United States Navy, has allowed LifePoint to develop a broadly applicable, rapid, on-site diagnostic test system. The first product simultaneously detects drugs of abuse and alcohol, and the initial three target markets - law enforcement, industrial workplace and medical emergency room - are estimated to be over \$1.6 billion.

This press release contains forward-looking statements regarding future events and the future performance of LifePoint, Inc. that involve risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, potential need for additional financing, FDA 510(k) clearance in medical markets, dependence on third parties for certain marketing efforts, and market acceptance. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.

LIFEPOINT(R) and IMPACT(R) are trademarks of LifePoint, Inc.

CONTACTS:

LifePoint, Inc.
Linda H. Masterson, CEO & President
(909) 418-3000 x 400

INVESTORS:

Cameron Associates
Lester Rosenkrantz
212-245-8800 ext. 212

e-mail: LifePoint@LFPT.com
Web site: www.LifePointInc.com

####